Ao final do trabalho e considerando os objetivos propostos pôde-se concluir que:
• Foi possível o desenvolvimento de um método para análise do mesilato de imatinibe em plasma utilizando a eletroforese capilar.
• A condição eletroforética estabelecida utilizou um capilar de sílica (46,5 cm de comprimento total, 38 cm de comprimento efetivo e 50 µm de diâmetro interno), tampão fosfato de sódio 50 mmol/L, pH 2,5 como eletrólito de corrida, injeção hidrodinâmica por 20 s a pressão de 50 mbar, voltagem de 30 kV, temperatura de 35 °C e detecção em 200 nm ( ).
• O procedimento de preparo da amostra foi baseado na extração líquido- líquido, utlizando como solvente extrator o éter metil-terc-butílico que forneceu
clean up satisfatório das amostras e os interferentes que ainda foram extraídos da
matriz foram bem resolvidos em relação ao fármaco e ao PI analisados.
• Os parâmetros de desempenho analítico, linearidade, precisão, exatidão, recuperação, limite de quantificação, especificidade e estabilidade avaliados na validação do método, cumpriram os requisitos preconizados na legislação vigente, a Resolução 899 da ANVISA (2003). Portanto, o método desenvolvido foi validado com sucesso.
• A aplicação do método proposto foi demonstrada na análise de amostras reais de plasma de pacientes portadores de Leucemia Mielóide Crônica.
57
REFERÊNCIAS
AHUJA, S. Overview of capillary electrophoresis in pharmaceutical analysis. In: AHUJA, S.; JIMIDAR, M.I. Capillary Electrophoresis Methods for Pharmaceutical Analysis. Elsevier Inc, cap. 1, p. 1-8, 2008.
ALI, I.; ABOUL-ENEIN, H.Y.; GUPTA, V.K. Precision in capillary electrophoresis. Analytical Letters, Philadelphia, v. 39, n. 11, p. 2345-2357, 2006.
ALTRIA, K.D. Capillary Electrophoresis Guidebook: Principles, operation and applications. New Jersey: 1996. 349 p.
ALTRIA, K.D.; FABRE H. Approaches to optimization of precision in capillary electrophoresis. Chromatographia, Wiesbaden, v. 40, n. 5/6, p. 313-320, 1995.
ANASTOS, N.; BARNETT, N.W.; LEWIS, S.W. Capillary electrophoresis for forensic drug analysis: A review. Talanta, Amsterdam, v. 67, p. 269-279, 2005.
APPERLEY, J.F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukemia. The Lancet Oncology, Nova Iorque, v. 8, p. 1018-1029, 2007.
ARAÚJO, P.; COUILLARD, F.; LEIRNES, E.; ASK, K.; BOKEVOLL, A.; FROYLAND, L. Experimental design considerations in quantification experiments by using the internal standard technique: Cholesterol determination by gas chromatography as a case study. Journal of Chromatography A, Amsterdam, v. 1121, p. 99-105, 2006.
AWIDI, A.; SALEM, I.I.; NAJIB, N.; MEFLEH, R.; TARAWNEH, B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: method’s comparison. Leukemia Research, Oxford, v. 34, p. 714-717, 2010.
BACCARANI, M.; SAGLIO, G.; GOLDMAN, J.; HOCHHAUSS, A.; SIMONSSON, B.; APPELBAUM, F.; APPERLEY, J.; CERVANTES, F.; CORTES, J.; DEININGER, M.; GRATWOHL, A.; GULHOT, F.; HOROWITZ, M.; HUGHES, T.; KANTARJIAN, H.; LARSON, R.; NIEDERWIESER, D.; SILVER, R.; HEHLMANN, R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the european leukemiaNet. Blood, Washington, v. 108, n. 6, p. 1809-1820, 2006.
58
BAHKTIAR, R.; KHEMANI, L.; HAYES, M.; BEDMAN, T.; TSE, F. Quantification of the antileukemia drug STI571 (Gleevec TM) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure an liquid chromatography tandem-mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 28, p. 1183-1194, 2002.
BAKHTIAR, R.; LOHNE, J.; RAMOS, L.; KHEMANI, L.; HAYES, M.; TSE, F. High- throughput quantification of the anti-leukemia drug STI571 (Gleevec®) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B, Amsterdam, v. 768, p. 325-340, 2002.
BARBOZA, L.P.; SOUZA, J.M.; SIMÕES, F.V.; BRAGANÇA, I.C.; ABDELHAY, E. Análise dos transcritos da translocação t(9;22) em leucemia mielóide crônica. Revista Brasileira Hematologia e Hemoterapia, Rio de Janeiro, v. 22, n. 2, p. 89- 98, 2000.
BONATO, P.S. Recent advances in the determination of enantiomeric drugs and their metabolites in biological fluids by capillary electrophoresis-mediated microanalysis. Electrophoresis, Weinheim, v. 24, p. 4078-4094, 2003.
BOODY, A.V.; SLUDDEN, J.; GRIFFIN, M.J.; GARNER, C.; KENDRICK, J.; MISTRY, P.; DUTREIX, C.; NEWELL, D.R.; O’BRIEN, S.G. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clinical Cancer Research, Philadelphia, v. 13, n. 14, p. 4164 – 4169, 2007.
BOONE, C.M.; WATERVAL, J.C.M.; LINGEMAN, H.; ENSING, K.; UNDERBERG, W.J.M. Capillary electrophoresis as a versatile tool for the bioanalysis of drugs – a review. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 20, p. 831-863, 1999.
BORGES, J.H.; BORGES-MIGUEL, T.M.; RODRIGUEZ-DELAGADO, A.R.; CIFUENTES, A. Sample treatments prior to capillary electrophoresis-mass spectrometry. Journal of Chromatography A, Amsterdam, v. 1153, p. 214-226, 2007.
BRAGGIO, S.; BARNABY, R.J.; GROSSI, P.; CUGOLA, M. A strategy for validation of bianalytical methods. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 14, p. 375-388, 1996.
59
BRASIL. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução n° 899 de 29 de maio de 2003. Guia para validação de métodos analíticos e bioanalíticos.
BREADMORE, M.C. Eletrokinetic and hydrodynamic injection: making the right choice for capillary electrophoresis. Bioanalysis, Londres, v. 1, n. 5, p. 889-894, 2009.
CAO, J.; HONG, F.; CHENG, P. Numerical analysis on the influence factors of sample stacking in capillary electrophoresis. Chinese Journal of Chromatography, v. 25, n. 2, p. 183-188, 2007.
CAUSON, R. Validation of chromatographic methods in biomedical analysis- Viewpoint and discussion. Journal of Chromatography B, Amsterdam, v. 686, p. 175-180, 1997.
CHABNER, B.A.; AMREIN, P.C.; DRUKER, B.J.; MICHAELSON, M.D.; MITSIADES, C.S.; GOSS, P.E.; RYAN, D.P.; RAMACHANDRA, S.; RICHARDSON, P.G.; SUPKO, J.G., WILSON, W.H. Agentes antineoplásicos. In: Goodman & Gilman. As bases farmacológicas da terapêutica. 11 ed. Rio de janeiro: MCGRAW, H., 2007, p. 1185-1264.
CHIEN, R.L.; BURGI, D.S. Field amplified sample injection in high performance capillary electrophoresis. Journal of Chromatography, Amsterdam, v. 559, p. 141- 152, 1991.
COHEN, M.H.; WILLIAMS, G.; JOHNSON, J.R.; DUAN, J; GOBBURU, J.; RAHMAN, A.; BENSON, K.; LEIGHTON, J.; KIM, S.K.; WOOD, R.; ROTHMANN, M.; CHEN, G.; U, K.M.; STATEN, A.M.; PAZDUR, R. Approval summary for imatinib mesylate capsules in the treatment of Chronic Myelogenous Leukemia. Clinical Cancer Research, Philadelphia, v. 8, p. 935-942, 2002.
CRUCES-BLANCO, C.; GÁMIZ-GRACIA, L.; GARCÍA-CAMPAÑA, A.M.; Applications of capillary electrophoresis in forensic analytical chemistry. Trends in Analytical Chemistry, Amsterdam, v. 26, n. 3, p. 215-226, 2007.
CUADROS-RODRÍGUEZ, L.; GÁMIZ-GRACIA, L.; ALMANSA-LÓPEZ, E.M.; BOSQUE-SENDRA, J.M. Calibration in chemical measurement processes. II. A methodological approach. Trends in Analytical Chemistry, Amsterdam, v. 20, n. 11, p. 620-636, 2001.
60
DAVIES, A.; HAYES, A.K.; KNIGHT, K.; WATMOUGH, S.J.; PIRMOHAMED, M.; CLARK, R.E. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP 74588) in human plasma by ultra-violet high performance liquid chromatography. Leukemia Research, Oxford, v. 34, p. 702-707, 2010.
DE FRANCIA, S.; D’AVOLIO, A.; DE MARTINO, F.; PIRRO, E.; BAIETTO, L.; SICCARDI, M.; SIMIELE, M.; RACCA, S.; SAGLIO, G.; DI CARLO, F.; DI PERRI, G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of Chromatography B, Amsterdam, v. 877, p. 1721–1726, 2009.
DEININGER, M.W.N.; DRUKER, B.J. Specific targeted therapy of Chronic Myelogenous Leukemia with imatinib. Pharmacological Reviews, Bethesda, v. 55, n. 3, p. 401-423, 2003.
DRUKER, B.J.; TALPAZ, M.; RESTA, D.J.; PENG, B.; BUCHDUNGER, E.; FORD, J.M.; LYDON, N.B.; KANTARJIAN, H.; CAPDEVILLE, R.; OHNO-JONES, S.; SAWYERS, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine, Waltham, v. 344, n. 14, p. 1031-1037, 2001.
DRUKER, B.J. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. European Journal of Cancer, Oxford, v. 38, n. 5, p. S70-S76, 2002.
FALLER, T.; ENGELHARDT, H. How to achieve higher repeatability and reproducibility in capillary electrophoresis. Journal of Chromatography A, Amsterdam, v. 853, p. 83-94, 1999.
FEKETE, A.; SCHMITT-KOPPLIN, P. Capillary Electrophoresis. In: PICÓ, Y. Food Toxicants Analysis. Elsevier Inc., cap. 15, p. 561-597, 2007.
FRONTIERS IN BIOSCIENCE. Representação do modelo da dupla camada. Disponível em http://www.bioscience.org/2009/v14/af/3500/figures.htm
GLIVEC: mesilato de imatinibe. Suíça: Novartis Pharma Stein AG. Bula de remédio.
GOLDMAN, J.M. Chronic Myeloid Leukaemia. Medicine, Philadelphia, v. 37, n.4, p.195-197, 2009.
61
GÓMEZ, J.E.; SANDOVAL, J.E. The effect of conditioning of fused-silica capillaries on their eletrophoretic performance. Electrophoresis, Weinheim, v. 29, p. 381-392, 2008.
GSCHWIND, H.P.; PFAAR, U.; WALDMEIER, F.; ZOLLINGER, M.; SAYER, C.; ZBINDEN, P.; HAYES, M.; POKORNY, R.; SEIBERLING, M.; BEN-AM, M.; PENG, B.; GROSS, G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metabolism and Disposition, Bethesda, v. 33, n. 10, p. 1503- 1512, 2005.
GUETENS, G.; DE BOECK, G.; HIGHLEY, M.; DUMEZ, H.; OOSTEROM, A.T.V.; DE BRUIJN, E.A. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry. Journal of Chromatography A, Amsterdam, v. 1030, p. 27-34, 2003.
GUETENS, G.; PRENEN, H.; DE BOECK, G.; VAN OOSTEROM, A.; SCHOFFSKI, P.; HIGHLEY, M.; DE BRUIJN, E.A. Simultaneos determination of AMN 107 and imatinib in cultured tumour cells using an isocratic high performance liquid chromatography procedure with UV detection. Journal of Chromatography B, Amsterdam, v. 846, p. 341-345, 2007.
HADLEY, M.; GILGES, M.; SENIOR, J.; SHAH, A.; CAMILLERI, P. Capillary electrophoresis in the pharmaceutical industry: applications in discovery and chemical development. Journal of Chromatography B, Amsterdam, v. 745, p. 177- 188, 2000.
HAEFELFINGER, P. Limits of the internal standard technique in chromatography. Journal of Chromatography, Amsterdam, v. 218, p. 73-81, 1981.
HAOUALA, A.; ZANOLARI, B.; ROCHAT, B.; MONTEMURRO, M.; ZAMAN, K.; DUCHOSAL, M.A.; RIS, H.B.; LEYVRAZ, S.; WIDMER, N.; DECOSTERD, L.A. Therapeutic drug monitoring of new targeted anticancer agents imatinib, nilotinib, dasatinib, sutinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography B, Amsterdam, v. 877, p. 1982-1996, 2009.
HEHLMANN, R.; HOCHHAUS, A.; BACCARANI, M. Chronic myeloid leukaemia. The Lancet, Nova Iorque, v. 370, p. 342-350, 2007.
62
HEMPEL, G. Strategies to improve the sensitivity in capillary electrophoresis for the analysis of drugs in biological fluids. Electrophoresis, Weinheim, v. 21, p. 691-698, 2000.
HERNÁNDEZ-BORGES, J.; BORGES-MIQUEL, T.M.; RODRIGUEZ-DELGADO, M.A.; CIFUENTES, A. Sample treatments prior to capillary electrophoresis-mass spectrometry. Journal of Chromatography A, Amsterdam, v. 1153, p. 214-226, 2007.
ISSAQ, H.J. A decade of capillary electrophoresis. Electrophoresis, Weinheim, v. 21, p. 1921-1939, 2000.
IVANOVIC, D.; MEDENICA, M.; JANCIC, B.; MALENOVIC, A. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Gleevec® capsules. Journal of Chromatography B, Amsterdam, v. 800, p. 253-258, 2004.
JANINI, G.M.; ISSAQ, H.J. The buffer in capillary zone electrophoresis. In: Norberto A. Guzman. Capillary Electrophoresis Technology. Nova Iorque: MARCEL DEKKER, INC., 1993, p. 119-160.
JIMIDAR, M.I. Theoretical considerations in performance of various modes of CE. Separation Science and Technology, Philadelphia, v. 9, p. 9-42, 2008
JIMIDAR, MI.; HEYLEN, P.; SMET, M.D. Method validation. Separation Science and Technology, Philadelphia, v. 8, p. 441-458, 2007.
KUJAWSKI, L.A.; TALPAZ, M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine & Growth Factors Reviews, Oxford, v. 18, p. 459-471, 2007.
KATAOKA, H. New trends in sample preparation for clinical and pharmaceutical analysis. Trends in Analytical Chemistry, Amsterdam, v. 22, n. 4, 2003.
KUHN, R.; HOFFSTETTER-KUHN, S. Capillary Electrophoresis principles and practice. Alemanha: Springer-Verlag, 1993. 370 p.
63
LABORATOIRE SUISSE D’ANALYSE DU DOPAGE. Representação da separação por CE. Disponível em: http://www.doping.chuv.ch/en/lad_home/lad-prestations- laboratoire/lad-prestations-laboratoire-appareils/lad-prestations-laboratoire-appareils- ec.htm
LARSON, R.A.; DRUKER, B.J.; GUILHOT, F.; O’BRIEN, S.G.; RIVIERI, G.J.; KRAHNKE, T.; GATHMANN, I.; WANG, Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, Washington, v. 111, n. 8, p. 4022-4028, 2008.
LEHMANN, R.; VOELTER, W.; LIEBICH, H.M. Capillary electrophoresis in clinical chemistry. Journal of Chromatography B, Amsterdam, v. 697, p. 3-35, 1997.
LI, S.F.Y. Capillary Electrophoresis: Principles, practice and applications. Amsterdam: Elsevier, 1993. 583 p.
MALLAMPATI, S.; PAUWELS, J.; HOOGMARTENS, J.; VAN SCHEPDAEL, A. CE in impurity profiling of drugs. Separation Science and Technology, Philadelphia, v. 9, p. 259-315, 2008.
MAYER, B.X.; How to increase precision in capillary electrophoresis. Journal of Chromatography A, Amsterdam, v. 907, p. 21-37, 2001.
MEDENICA, M.; JANCIC, B.; IVANOVIC, D.; MALENOVIC, A. Experimental design in reversed-phase high-performance liquid-chromatographic analysis of imatinib mesylate and its impurity. Journal of Chromatography, Amsterdam, v. 1031, p. 243-248, 2004.
MEHTA, A.C. Drug determination in biological fluids – approaches to method validation. Talanta, Amsterdam, v. 34, n. 7, p. 609-613, 1987.
MEHTA, A.C. The how and why of therapeutic drug monitoring. Analytical Proceedings Including Analytical Communications, v. 32, p. 347-351, 1995.
MELO, J.V.; CHUAH, C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Letters, Irlanda, v. 249, p. 121-132, 2007.
64
O’BRIEN, S.G.; GUILHOT, F.; LARSON, R.A.; GATHMANN, I.; BACCARANI, M.; CERVANTES, F.; CORNELISSEN, J.J.; FISCHER, T. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, Waltham, v. 348, p.994- 1004, 2003.
O’DWYER, M.E.; DRUKER, B.J. STI571: an inhibitor of the bcr-abl tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncology, Nova Iorque, v. 1, p. 207-211, 2000.
O’FLAHERTY, B. NUNNALLY, B.K. Equipment considerations for capillary electrophoresis. Separation Science and Technology, Philadelphia, v. 9, p. 43-62, 2008.
OOSTENDORP, R.L.; BEIJNEM, J.H.; SCHELLENS, J.H.M.; VAN TELLINGEN, O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography, Sussex, v. 21, p. 747-754, 2007.
PARISE, R.A.; RAMANATHAN, R.K.; HAYES, M.J.; EGORIN, M.J. Liquid chromatographic–mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Journal of Chromatography B, Amsterdam, v. 791, p. 39-44, 2003.
PEDERSEN-BJEGAARD, S.; RASMUSSEN, K.E.; HALVORSEN, T.G. Liquid-liquid extraction procedures for sample enrichment in capillary zone electrophoresis. Journal of Chromatography A, Amsterdam, v. 902, p. 91-105, 2000.
PENG, B.; LLOYD, P.; SCHRAN, H. Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics, Auckland, v.9, n. 44, p. 879-894, 2005.
PENG, B.; HAYES, M.; RESTA, D.; RACINE-POON, A.; DRUKER, B.J.; TALPAZ, M.; SAWYERS, C.L.; ROSAMILIA, M.; FORD, J.; LLOYD, P.; CAPDEVILLE, R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology, Alexandria, p. 935-942, 2004.
PETERS, F.T.; DRUMMER, O.H.; MUSSHOFF, F. Validation of new methods. Forensic Science International, Irlanda, v. 165, p. 216-224, 2007.
65
RADICH, J.P.; HONGYUE, D.; MAO, M.; OEHLER, V.; SCHELTER, J.; DRUKER, B.; SAWYERS, C.; SHAH, N.; STOCK, W.; WILLMAN, C.L.; FRIEND, S.; LINSLEY, P.S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of USA, Washington, v. 103, n. 8, p. 2794–2799, 2006.
RASMUSSEN, K. E.; PEDERSEN-BJERGAARD, S. Developments in hollow fiber- based, liquid-phase microextraction. Trends in Analytical Chemistry, Amsterdam, v. 23, p. 1-10, 2004.
REN, R. Mechanisms of bcr-abl in the pathogenesis of chronic myeloid leukemia. Nature, Londres, v. 5, p. 172-183, 2005.
RODRIGUEZ-FLORES, J.; BERZAS, J.J.; CASTAÑEDA, G.; RODRÍGUEZ, N. Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. Journal of Chromatography B, Amsterdam, v. 794, p. 381-388, 2003.
RODRIGUEZ-FLORES, J.; NEVADO, J.J.B.; SALCEDO, A.M.C.; DÍAZ, M.P.C. Nonaqueous capillary electrophoresis method for the analysis of Gleevec and its main metabolite in human urine. Journal of Chromatography A, Amsterdam, v. 1068, p. 175-182, 2005.
ROSASCO, M.; MOYANO, M.; PIZZORNO, M.; SEGALL, A. Validation of an HPLC method for the determination of imatinib mesylate in pharmaceutical dosage. Journal of Liquid Chromatography & Related Technologies, Philadelphia, v. 28, n. 20, p. 3283-3292, 2005.
ROTH, O.; SPREUX-VAROQUAUX, O.; BOUCHET, S.; ROUSSELOT, P.; CASTAIGNE, S.; RIGAUDEAU, S.; RAGGUENEAU, V.; THEROND, P.; DEVILLIER, P.; MOLLIMARD, M.; MANEGLIER, B. Imatinib assay by HPLC with photodiode- array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC/MS-MS. Clinica Chimica Acta, Amsterdam, v. 411, p. 140-146, 2010.
SHAH, V.P.; MIDHA, K.K.; FINDLAY, J.W.A.; HILL, H.M.; HULSE, J.D.; McGILVERAY, I.J.; McKAY, G.; MILLER, K.J.; PATNAIK, R.N.; POWELL, M.L.; TONELLI, A.; VISWANATHAN, C.T.; YACOBI, A. Bionalytical method validation – a revisit with a decade of progress. Pharmaceutical Research, Nova Iorque, v. 17, p. 1551-1557, 2000.
66
SCHLEYER, E.; PURSCHE, S.; KÖHNE, C.H.; SCHULER, U.; RENNER, U.; GSCHAIDMEIER, H.; FREIBERG-RICHTER, J.; LEOPOLD, T.; JENKE, A.; BONIN, M.; BERGEMANN, T.; LE COUTRE, P.; GRUNER, M.; BORNHÄUSER, M.; OTTMANN, O.G.; EHNINGER, G. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. Journal of Chromatography B, Amsterdam, v. 799, p. 23-36, 2004.
SILVA, J.A.F.; COLTRO, W.K.T.; CARRILHO, E.; TAVARES, M.F.M. Terminologia para as técnicas analíticas de eletromigração em capilares. Química Nova, São Paulo, v. 30, n. 3, p. 740-744, 2007.
SIMONET, B.M.; RÍOS, A.; VALCÁRCEL, M. Enhancing sensitivity in capillary electrophoresis. Trends in Analytical Chemistry, Amsterdam, v. 22, n. 10, 2003.
SNIEHOTTA, M.; SCHIFFER, E.; ZÜRBIG, P.; NOVAK, J.; MISCHAK, H. CE-a multifunctional application for clinical diagnosis. Electrophoresis, Weinheim, v. 28, p.1407-1417, 2007.
SOUZA, C.A.; PAGNANO, K. Os desafios no tratamento da leucemia mielóide crônica na era do mesilato de imatinibe. Revista Brasileira de Hematologia e Hemoterapia, Rio de Janeiro, v. 26, n. 4, p. 282-284, 2004.
SZCZEPEK, W.J.; KOSMACINSKA, B.; BIELEJEWSKA, A.; LUNIEWSKI, W.; SCARZYNSKI, M.; ROZMARYNOWSKA, D. Identification of imatinib mesylate degradation products obtained under stress conditions. Journal of Pharmaceuticals and Biomedical Analysis, Amsterdam, v. 43, p. 1682-1691, 2007.
SWINNEY, K.; BORNHOP, D.J. Detection in capillary electrophoresis. Electrophoresis, Weinheim, v. 21, p. 1239-1250, 2000.
TAGLIARO, F.; TURRINA, S.; SMITH, F.P. Capillary electrophoresis: principles and applications in illicit drug analysis. Forensic Science International, Irlanda, v. 77, p.211-229, 1996.
TAVARES, M.F.M. Eletroforese capilar: conceitos básicos. Química Nova, São Paulo, v. 19, n. 2, p. 173-181, 1996.
TAVARES, M.F.M. Mecanismos de separação em eletroforese capilar. Química Nova, São Paulo, v. 20, n.52, p. 493-511, 1997.
67
TITIER, K.; PICARD, S.; DUCINT, D.; TEILHET, E.; MOORE, N. BERTHAUD, P.; MAHON, F.X.; MOLIMARD, M. Quantification of imatinib in human plasma by high- performance liquid chromatography –tandem mass spectrometry. Therapeutic Drug Monitoring, Philadelphia, v. 27, n. 5, p. 634-640, 2005.
VADERA, N.; SUBRAMANIAN, G.; MUSMADE, P. Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage-form. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 43, p. 722- 726, 2007.
VELPANDIAN, T.; MATHUR, R.; AGARWAL, N.K.; ARORA, B.; KUMAR, L.; GUPTA, S.K. Development and validation of a simple liquid chromatographic method with ultraviolet detection for determination of Imatinib in biological samples. Journal of Chromatography B, Amsterdam, v. 804, p. 431-434, 2004.
VIVEKANAND, V.V.; RAO, D.S.; VAIDYANATHAN, G.; SEKHAR, N.M.; KELKAR, S.A.; PURANIK, P.R. A validated LC method for imatinib mesylate. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 33, p. 879-889, 2003.
VOLPE, G.; PANUZZO, C.; ULISCIANI, S.; CILLONI, D. Imatinib resistance in CML. Cancer Letters, Irlanda, v. 274, p. 1-9, 2009.
WIDMER, N.; BÉGUIN, A.; BUCLIN, R.T.; KOVACSOVICS, T.; DUCHOSAL, M.A.; LEYVRAZ, S.; ROSSELET, A.; BIOLLAZ, J.; DECOSTERD, L.A. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. Journal of Chromatography